BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 14667200)

  • 21. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
    Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
    Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
    Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
    Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821.
    Chang M; Raimondi SC; Ravindranath Y; Carroll AJ; Camitta B; Gresik MV; Steuber CP; Weinstein H
    Leukemia; 2000 Jul; 14(7):1201-7. PubMed ID: 10914543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.
    Nørgaard JM; Langkjer ST; Palshof T; Pedersen B; Hokland P
    Eur J Haematol; 2001 Mar; 66(3):160-7. PubMed ID: 11350484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
    Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Schmetzer H
    Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
    Byrd JC; Mrózek K; Dodge RK; Carroll AJ; Edwards CG; Arthur DC; Pettenati MJ; Patil SR; Rao KW; Watson MS; Koduru PR; Moore JO; Stone RM; Mayer RJ; Feldman EJ; Davey FR; Schiffer CA; Larson RA; Bloomfield CD;
    Blood; 2002 Dec; 100(13):4325-36. PubMed ID: 12393746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.
    Tavernier E; Le QH; Elhamri M; Thomas X
    Leuk Res; 2003 Mar; 27(3):205-14. PubMed ID: 12537972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.
    Goldstone AH; Burnett AK; Wheatley K; Smith AG; Hutchinson RM; Clark RE;
    Blood; 2001 Sep; 98(5):1302-11. PubMed ID: 11520775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
    Scholl C; Schlenk RF; Eiwen K; Döhner H; Fröhling S; Döhner K;
    Haematologica; 2005 Dec; 90(12):1626-34. PubMed ID: 16330435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years.
    Schaich M; Illmer T; Aulitzky W; Bodenstein H; Clemens M; Neubauer A; Repp R; Schäkel U; Soucek S; Wandt H; Ehninger G;
    Haematologica; 2002 Aug; 87(8):808-15. PubMed ID: 12161356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia.
    Demirer T; Petersen FB; Bensinger WI; Appelbaum FR; Fefer A; Rowley S; Sanders J; Chauncey T; Storb R; Lilleby K; Buckner CD
    Bone Marrow Transplant; 1996 Jul; 18(1):29-34. PubMed ID: 8831992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
    Filipits M; Suchomel RW; Zöchbauer S; Brunner R; Lechner K; Pirker R
    Clin Cancer Res; 1997 Aug; 3(8):1419-25. PubMed ID: 9815827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients.
    Colovic M; Colovic N; Radojkovic M; Stanisavljevic D; Kraguljac N; Jankovic G; Tomin D; Suvajdzic N; Vidovic A; Atkinson HD
    Ann Hematol; 2012 Sep; 91(9):1363-70. PubMed ID: 22592651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HLA-DR antigen-negative acute myeloid leukemia.
    Wetzler M; McElwain BK; Stewart CC; Blumenson L; Mortazavi A; Ford LA; Slack JL; Barcos M; Ferrone S; Baer MR
    Leukemia; 2003 Apr; 17(4):707-15. PubMed ID: 12682628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia.
    He XY; Pohlman B; Lichtin A; Rybicki L; Kalaycio M
    Leukemia; 2003 Jun; 17(6):1078-84. PubMed ID: 12764371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia.
    Xiang L; Li M; Liu Y; Cen J; Chen Z; Zhen X; Xie X; Cao X; Gu W
    Ann Hematol; 2013 Aug; 92(8):1063-9. PubMed ID: 23515710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
    Tan RM; Quah TC; Aung L; Liang S; Kirk RC; Yeoh AE
    Pediatr Blood Cancer; 2007 Mar; 48(3):262-7. PubMed ID: 16602120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
    Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
    Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Not the presence but the amount of clonal DNA detectable in remission of acute myeloid leukemia is predictive for relapse.
    Reif SW; Wiesner D; Duell T; Mittermueller J; Schmetzer HM
    Eur J Haematol; 2001 Oct; 67(4):207-20. PubMed ID: 11860441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.